Germany
Japan
United Kingdom
China
Antibodies
Anti-LGR5 mouse mAb, clone OTI2A2, DyLight 488 conjugated
| Applications | FC |
| Reactivities | Human, Mouse |
| Conjugation | DyLight 488 |
Rabbit Polyclonal PD-L1 Antibody
| Applications | FC, IF, IHC, WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
| Immunogen | PD-L1 antibody was raised against a 17 amino acid synthetic peptide from near the center of human PD-L1. The immunogen is located within amino acids 60 - 110 of PD-L1. |
Anti-LGR5 mouse mAb, clone OTI2A2, DyLight633 conjugated
| Applications | FC |
| Reactivities | Human, Mouse |
| Conjugation | DyLight 633 |
Rabbit Polyclonal Anti-Angiotensin II Receptor Type-1 (extracellular)
| Applications | FC, IF, IHC, WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
| Immunogen | Peptide NSSTEDGIKRIQDDC, corresponding to amino acid residues 4-18 of human AT1 receptor. Extracellular, N-terminus. |
HER2 (ERBB2) Mouse Monoclonal Antibody, clone 3C2-4
| Applications | FC |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
HER2 (ERBB2) Mouse Monoclonal Antibody, clone 3G11-14
| Applications | FC |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
HER2 (ERBB2) Mouse Monoclonal Antibody, clone 4A5-19
| Applications | FC |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
HER2 (ERBB2) Mouse Monoclonal Antibody, clone 5F4-15
| Applications | FC |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
HER2 (ERBB2) Mouse Monoclonal Antibody, clone 5G12-21
| Applications | FC |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
HER2 (ERBB2) Mouse Monoclonal Antibody, clone 6F5-23
| Applications | FC |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
HER2 (ERBB2) Mouse Monoclonal Antibody, clone 6H8-22
| Applications | FC |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
HER2 (ERBB2) Mouse Monoclonal Antibody, clone 8E8-2
| Applications | FC |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
HER2 (ERBB2) Mouse Monoclonal Antibody, clone 8F6-6
| Applications | FC |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
HER2 (ERBB2) Mouse Monoclonal Antibody, clone 9G5-20
| Applications | FC |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
HER2 (ERBB2) Mouse Monoclonal Antibody, clone 12G4-15
| Applications | FC |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
HER2 (ERBB2) Mouse Monoclonal Antibody, clone 15C4-8
| Applications | FC |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
HER2 (ERBB2) Mouse Monoclonal Antibody, clone 16F12-11
| Applications | FC |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
USD 524.00
In Stock
USD 440.00
2 Weeks
Goat Polyclonal Anti-Vimentin Antibody
| Applications | FC, IF, WB |
| Reactivities | Human (Expected from sequence similarity: Mouse, Rat, Dog, Pig, Cow) |
| Conjugation | Unconjugated |
| Immunogen | The immunogen for Anti-Vimentin Antibody: Peptide with sequence C-QVINETSQHHDDLE, from the C Terminus of the protein sequence according to NP_003371.2. |
Rabbit Polyclonal Anti-Serotonin Transporter (SERT) (extracellular)
| Applications | FC, IF, IHC, WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
| Immunogen | Peptide (C)EMRNEDVSEVAKD, corresponding to amino acids residues 388-400 of rat Serotonin Transporter. 4th extracellular loop. |
Rabbit polyclonal CP Antibody (Center)
| Applications | FC, IHC, WB |
| Reactivities | Human, Mouse |
| Conjugation | Unconjugated |
| Immunogen | This CP antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 547-577 amino acids from the Central region of human CP. |
Rabbit polyclonal CYP27B1 Antibody (C-term)
| Applications | FC, IHC, WB |
| Reactivities | Human, Mouse |
| Conjugation | Unconjugated |
| Immunogen | This CYP27B1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 482-508 amino acids from the C-terminal region of human CYP27B1. |
Rabbit Polyclonal Anti-Nectin-1 (extracellular)
| Applications | FC, IF, IHC, WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
| Immunogen | Peptide (C)GKPPSVVSWETRLK, corresponding to amino acid residues 177- 190 of human nectin-1. Extracellular, N-terminus. |
Rabbit Polyclonal Anti-Cholecystokinin B Receptor (extracellular)
| Applications | FC, IHC, WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
| Immunogen | Peptide CETPRIRGTGTRELE, corresponding to amino acid residues 39-53 of mouse Cholecystokinin B Receptor. Extracellular, N-terminus. |
Mouse Monoclonal iNOS Antibody (4E5)
| Applications | ELISA, FC, IHC, WB |
| Reactivities | Human, Mouse |
| Conjugation | Unconjugated |
TA336918 is a replacement of AM06772PU-N.
Rabbit Polyclonal 53BP1 Antibody
| Applications | FC, WB |
| Reactivities | Human, Mouse |
| Conjugation | Unconjugated |
| Immunogen | The epitope recognized by this antibody maps to a region between residues 350 and 400 of human 53BP1 [NP_005648.1 (GeneID 7158)]. |
Rabbit polyclonal ENOA Antibody (N-term)
| Applications | FC, IF, WB |
| Reactivities | Human, Mouse |
| Conjugation | Unconjugated |
| Immunogen | This ENOA antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 33-60 amino acids from the N-terminal region of human ENOA. |
Rabbit polyclonal GC Antibody (Center)
| Applications | FC, IHC, WB |
| Reactivities | Human, Mouse |
| Conjugation | Unconjugated |
| Immunogen | This GC antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 337-365 amino acids from the Central region of human GC. |
Rabbit Polyclonal CXCR4 Antibody
| Applications | FC, IF, IHC, WB |
| Reactivities | Human, Mouse |
| Conjugation | Unconjugated |
| Immunogen | CXCR4 antibody was raised against a peptide corresponding to 14 amino acids near the amino terminus of human CXCR4. The immunogen is located within the first 50 amino acids of CXCR4. |
Active filters
Reactivities
- Mouse
Applications
- FC
Filter by
Target Symbol
- ERCC1 (115)
- L1CAM (85)
- CTNNB1 (81)
- ERBB2 (77)
- PNMT (65)
- SENP2 (65)
- PDCD1 (64)
- LGR5 (61)
- ACAT2 (55)
- RNF144B (55)
- SQSTM1 (55)
- TTLL12 (55)
- UBE2E3 (55)
- ZFP36 (55)
- CDK2 (50)
- IGF2BP2 (50)
- KATNB1 (50)
- MAPK7 (50)
- MEIS3 (50)
- MOB3B (50)
- NPR3 (50)
- PACSIN3 (50)
- PFKP (50)
- PRKCE (50)
- RPN1 (50)
- SMS (50)
- BTK (49)
- ACY1 (45)
- AK5 (45)
- ARHGAP25 (45)
- BECN1 (45)
- DSTN (45)
- EPM2AIP1 (45)
- HOXC11 (45)
- LDLRAP1 (45)
- LIMK1 (45)
- NRBP1 (45)
- PDE2A (45)
- PIK3AP1 (45)
- SIRT5 (45)
- SNAP25 (45)
- SNX9 (45)
- SRR (45)
- STAT5A (45)
- TAL1 (45)
- AK4 (40)
- ARFGAP1 (40)
- CHCHD5 (40)
- CRYAB (40)
- DNAJA2 (40)
- ERCC4 (40)
- FBXO21 (40)
- FSHB (40)
- GPHN (40)
- GRHPR (40)
- MSI1 (40)
- NDUFA7 (40)
- PSMC3 (40)
- PTPRE (40)
- SOCS3 (40)
- STAT4 (40)
- AKT1 (38)
- SNAI2 (38)
- DPP3 (36)
- NGFR (36)
- POR (36)
- ALDH1L1 (35)
- APP (35)
- ATG3 (35)
- CDKN3 (35)
- CHEK2 (35)
- CLPP (35)
- DLD (35)
- DNAJB1 (35)
- DPP9 (35)
- DYNC1LI1 (35)
- HID1 (35)
- HMOX2 (35)
- LCMT1 (35)
- LHX1 (35)
- MGRN1 (35)
- MIOX (35)
- NUBPL (35)
- OTUB2 (35)
- PLEK (35)
- PPM1B (35)
- PPP5C (35)
- PRKAR2A (35)
- PRKD2 (35)
- RASD2 (35)
- SNTA1 (35)
- TLE1 (35)
- TOMM34 (35)
- TRIM9 (35)
- ZFAND2B (35)
- AKR1A1 (30)
- AP2M1 (30)
- COMMD1 (30)
- EFNA2 (30)
- ELK3 (30)
Antibody Hosts
Isotypes
Clonalities
Conjugates
Knockout (KO) Validation
Modifications
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG2a format, for improved compatibility with existing reagents, assays and techniques. (33)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG2b format, for improved compatibility with existing reagents, assays and techniques. (15)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG1 format, for improved compatibility with existing reagents, assays and techniques. (13)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques. (8)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Hamster IgG format, for improved compatibility with existing reagents, assays and techniques. (7)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Hamster IgG2 format, for improved compatibility with existing reagents, assays and techniques. (3)
- This chimeric rabbit antibody was made using the variable domain sequences of the original rat IgG2a format, for improved compatibility with existing reagents, assays and techniques. (3)
- This chimeric hamster (Armenian) antibody was made using the variable domain sequences of the original Hamster IgG format, for improved compatibility with existing reagents, assays and techniques. (2)
- This reformatted rat antibody was made using the variable domain sequences of the original Rat IgG1 format, for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric mouse antibody was made using the variable domain sequences of the original Hamster IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Armenian Hamster IgG format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Armenian Hamster IgG format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Hamster format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Hamster IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG2a format, for improved compatibility with existing reagents, assays and techniques. (1)
- This is a chimeric antibody created to reduce immunogenicity during in vivo applications. (1)
- This is a chimeric mouse antibody, based on the original hamster IgG format, created for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted antibody was made using the variable domain sequences of the original rat IgG2b format, for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted mouse antibody was made using the variable domain sequences of the original Mouse IgG format, for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted rat antibody was made using the variable domain sequences of the original Rat IgG format, for improved compatibility with existing reagents, assays and techniques. (1)
Assay Types
Families
- Druggable Genome (5845)
- Transmembrane (1312)
- Transcription Factors (1136)
- Protein Kinase (810)
- Protease (656)
- ES Cell Differentiation/IPS (577)
- Stem cell - Pluripotency (414)
- Secreted Protein (267)
- Phosphatase (198)
- Adult stem cells (138)
- Stem cell relevant signaling - JAK/STAT signaling pathway (90)
- GPCR (89)
- Stem cell relevant signaling - DSL/Notch pathway (83)
- Ion Channels: Other (71)
- P450 (61)
- Embryonic stem cells (42)
- Ion Channels: Potassium (31)
- Cancer stem cells (28)
- Nuclear Hormone Receptor (18)
- Stem cell relevant signaling - TGFb/BMP signaling pathway (18)
- Induced pluripotent stem cells (16)
- Stem cell relevant signaling - Wnt Signaling pathway (6)
- Ion Channels: Cys-loop Receptors (2)
- Ion Channels: ATP Receptors (1)
Pathways
- Metabolic pathways (1271)
- Pathways in cancer (616)
- Focal adhesion (372)
- MAPK signaling pathway (367)
- Prostate cancer (365)
- Purine metabolism (327)
- Progesterone-mediated oocyte maturation (323)
- Endometrial cancer (285)
- Insulin signaling pathway (282)
- ErbB signaling pathway (281)
- Adherens junction (264)
- Cell cycle (256)
- Neurotrophin signaling pathway (254)
- Colorectal cancer (243)
- Tight junction (241)
- Pancreatic cancer (240)
- Chronic myeloid leukemia (236)
- Glycolysis / Gluconeogenesis (235)
- Regulation of actin cytoskeleton (235)
- Non-small cell lung cancer (227)
- Ubiquitin mediated proteolysis (219)
- Nucleotide excision repair (218)
- Wnt signaling pathway (214)
- Leukocyte transendothelial migration (210)
- Cell adhesion molecules (CAMs) (208)
- Jak-STAT signaling pathway (207)
- Endocytosis (200)
- Axon guidance (197)
- Acute myeloid leukemia (196)
- Fc epsilon RI signaling pathway (193)
- Fc gamma R-mediated phagocytosis (193)
- B cell receptor signaling pathway (191)
- Pyruvate metabolism (185)
- Pathogenic Escherichia coli infection (184)
- Alzheimer's disease (180)
- Bladder cancer (180)
- Small cell lung cancer (172)
- T cell receptor signaling pathway (169)
- Arginine and proline metabolism (160)
- Huntington's disease (157)
- Gap junction (154)
- Renal cell carcinoma (152)
- Oocyte meiosis (149)
- Thyroid cancer (147)
- Proteasome (145)
- Glioma (144)
- Melanoma (144)
- Apoptosis (141)
- Arrhythmogenic right ventricular cardiomyopathy (ARVC) (141)
- Adipocytokine signaling pathway (137)
- Type II diabetes mellitus (136)
- Valine (135)
- GnRH signaling pathway (132)
- mTOR signaling pathway (131)
- Chemokine signaling pathway (130)
- Tyrosine metabolism (128)
- leucine and isoleucine degradation (125)
- p53 signaling pathway (121)
- Toll-like receptor signaling pathway (117)
- Calcium signaling pathway (116)
- Glycine (110)
- serine and threonine metabolism (110)
- Basal cell carcinoma (106)
- Oxidative phosphorylation (106)
- Parkinson's disease (106)
- Melanogenesis (105)
- TGF-beta signaling pathway (96)
- Vascular smooth muscle contraction (96)
- Butanoate metabolism (90)
- VEGF signaling pathway (90)
- Fructose and mannose metabolism (85)
- Citrate cycle (TCA cycle) (82)
- Regulation of autophagy (82)
- Pentose phosphate pathway (80)
- Epithelial cell signaling in Helicobacter pylori infection (79)
- Fatty acid metabolism (77)
- Glutathione metabolism (77)
- Primary immunodeficiency (76)
- Tryptophan metabolism (76)
- Glyoxylate and dicarboxylate metabolism (75)
- Lysine degradation (75)
- Terpenoid backbone biosynthesis (75)
- Propanoate metabolism (70)
- Synthesis and degradation of ketone bodies (70)
- Natural killer cell mediated cytotoxicity (68)
- Cysteine and methionine metabolism (67)
- Porphyrin and chlorophyll metabolism (67)
- Pyrimidine metabolism (67)
- Cytokine-cytokine receptor interaction (63)
- DNA replication (62)
- Mismatch repair (61)
- Long-term depression (56)
- RNA degradation (56)
- Vibrio cholerae infection (56)
- Galactose metabolism (55)
- beta-Alanine metabolism (55)
- Drug metabolism - cytochrome P450 (53)
- Neuroactive ligand-receptor interaction (53)
- Renin-angiotensin system (53)
- Notch signaling pathway (52)
- Histidine metabolism (50)
- Inositol phosphate metabolism (50)
- N-Glycan biosynthesis (50)
- Retinol metabolism (48)
- Amyotrophic lateral sclerosis (ALS) (47)
- Antigen processing and presentation (47)
- Maturity onset diabetes of the young (46)
- Glycerolipid metabolism (45)
- SNARE interactions in vesicular transport (45)
- Prion diseases (43)
- Hypertrophic cardiomyopathy (HCM) (41)
- Amino sugar and nucleotide sugar metabolism (40)
- Ascorbate and aldarate metabolism (40)
- Long-term potentiation (40)
- One carbon pool by folate (40)
- Dilated cardiomyopathy (39)
- Hematopoietic cell lineage (37)
- Drug metabolism - other enzymes (36)
- Androgen and estrogen metabolism (35)
- Homologous recombination (35)
- Selenoamino acid metabolism (35)
- Starch and sucrose metabolism (35)
- Metabolism of xenobiotics by cytochrome P450 (33)
- Pantothenate and CoA biosynthesis (30)
- Base excision repair (27)
- PPAR signaling pathway (26)
- Complement and coagulation cascades (24)
- NOD-like receptor signaling pathway (23)
- Alanine (22)
- Spliceosome (22)
- aspartate and glutamate metabolism (22)
- Basal transcription factors (21)
- Arachidonic acid metabolism (20)
- Caffeine metabolism (20)
- Nicotinate and nicotinamide metabolism (20)
- Vitamin B6 metabolism (20)
- Cardiac muscle contraction (19)
- ABC transporters (17)
- ECM-receptor interaction (17)
- Lysosome (17)
- Glycosaminoglycan degradation (16)
- Viral myocarditis (16)
- Circadian rhythm - mammal (15)
- Hedgehog signaling pathway (15)
- Methane metabolism (15)
- Phosphatidylinositol signaling system (15)
- Riboflavin metabolism (15)
- Thiamine metabolism (15)
- Phenylalanine metabolism (11)
- Dorso-ventral axis formation (10)
- RIG-I-like receptor signaling pathway (10)
- leucine and isoleucine biosynthesis (10)
- Systemic lupus erythematosus (9)
- Glycosphingolipid biosynthesis - lacto and neolacto series (6)
- Nitrogen metabolism (6)
- Steroid biosynthesis (6)
- Keratan sulfate biosynthesis (5)
- Limonene and pinene degradation (5)
- Olfactory transduction (5)
- RNA polymerase (5)
- Cytosolic DNA-sensing pathway (4)
- Type I diabetes mellitus (4)
- Allograft rejection (2)
- Autoimmune thyroid disease (2)
- Asthma (1)
- D-Glutamine and D-glutamate metabolism (1)
- Folate biosynthesis (1)
- Glycerophospholipid metabolism (1)
- Graft-versus-host disease (1)
- Heparan sulfate biosynthesis (1)
- Other glycan degradation (1)
- Phenylalanine (1)
- Primary bile acid biosynthesis (1)
- Sphingolipid metabolism (1)
- tyrosine and tryptophan biosynthesis (1)